Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims
Snakebite envenoming is a neglected tropical disease that each year claims the lives of 80,000⁻140,000 victims worldwide. The only effective treatment against envenoming involves intravenous administration of antivenoms that comprise antibodies that have been isolated from the plasma of im...
Main Authors: | R. Manjunatha Kini, Sachdev S. Sidhu, Andreas Hougaard Laustsen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-12-01
|
Series: | Toxins |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6651/10/12/534 |
Similar Items
-
Cost of Manufacturing for Recombinant Snakebite Antivenoms
by: Timothy Patrick Jenkins, et al.
Published: (2020-07-01) -
Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms
by: Andreas Hougaard Laustsen, et al.
Published: (2018-07-01) -
Recent Advances in Next Generation Snakebite Antivenoms
by: Cecilie Knudsen, et al.
Published: (2018-04-01) -
An investigation of snakebite antivenom usage in Taiwan
by: Chih-Chuan Lin, et al.
Published: (2016-08-01) -
Snakebite: When the Human Touch Becomes a Bad Touch
by: Bryan G. Fry
Published: (2018-04-01)